Their next drug Vadadustat could be HUGE!!! It could be a 1.5 billion annual type drug. Their top line data from their Two Pivotal Phase 3 Studies in Japanese Patients with Anemia Due to Chronic Kidney Disease was SUPERB!!!. They are in stage 3 trials in the US. That read out data is due this year like second Q. If that data is good this stock will see $20 quick IMO.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.